

| PATIENT INFORMATION | PHYSICIAN INFORMATION |
|---|---|
| Patient Name: _____ | Physician Name: _____ |
| Address: _____ | Contact: _____ |
| City, State, Zip: _____ | NPI #: _____ |
| Phone #: _____ Secondary Phone #: _____ | Address: _____ |
| Patient SSN#: _____ Date of Birth: _____ | _____ |
| Weight (lbs): _____ Height (in.): _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | City, State, Zip Code |
| Allergies: _____ | Phone #: _____ |
| Primary Insurance: _____ | Alt Phone #: _____ |
| ID#: _____ Phone #: _____ | Fax #: _____ |
| Secondary Insurance: _____ | Email: _____ |
| ID#: _____ Phone #: _____ | Ship Rx to: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's home |
| FAX COPY OF INSURANCE CARD (FRONT & BACK) | |

| CLINICAL INFORMATION | | |
|---|--|-------------------------------|
| <p style="text-align: center;">ICD-10 Diagnosis</p> <input type="checkbox"/> L40.0 Psoriasis vulgaris <input type="checkbox"/> L40.8 Other psoriasis <input type="checkbox"/> L40.9 Psoriasis, unspecified <input type="checkbox"/> L40.5 Psoriatic arthritis <input type="checkbox"/> L73.2 Hidradenitis suppurativa | Date of Diagnosis: _____ Date of negative TB test: _____ HBV: <input type="checkbox"/> Yes <input type="checkbox"/> No BSA affected (%): _____ Affected areas: <input type="checkbox"/> Head <input type="checkbox"/> Neck <input type="checkbox"/> Palms <input type="checkbox"/> Soles <input type="checkbox"/> Genitalia Comorbidities: _____ Medication Reconciliation: _____ | |
| Prior Treatment/Therapy (If Any) | Reason for Discontinuation | Start and End Date of Therapy |
| _____ | _____ | _____ |
| _____ | _____ | _____ |
| _____ | _____ | _____ |
| FAX COPY OF ALL RELATED CLINICAL/LAB INFO | | |

| MEDICATION | DIRECTIONS | QTY | REFILLS |
|--|--|--|---------|
| <input type="checkbox"/> STELARA® USTEKINUMAB | <input type="checkbox"/> Inject 45 mg subcutaneously on day 1 (≤ 100 kg) <input type="checkbox"/> Inject 90 mg subcutaneously on day 1 (>100 kg) | <input type="checkbox"/> 1x45 mg/0.5 mL PFS <input type="checkbox"/> 1x90 mg/mL PFS | 0 |
| | <input type="checkbox"/> Inject 45 mg SQ on day 29 and every 12 weeks after (≤ 100 kg) <input type="checkbox"/> Inject 90 mg SQ on day 29 and every 12 weeks after (>100 kg) | | |
| Patient eligible to self-administer medication? <input type="checkbox"/> Yes <input type="checkbox"/> No | | | |
| <input type="checkbox"/> TALTZ® IXEKIZUMAB | <input type="checkbox"/> Weeks 0-2: Inject 160 mg (2x80 mg) SQ on week 0, & inject 80 mg SQ on week 2 | <input type="checkbox"/> 3x80 mg/mL Autoinjectors | 0 |
| | <input type="checkbox"/> Weeks 4-10: Inject 80 mg SQ on week 4, & every two weeks after through week 10 | <input type="checkbox"/> 2x80 mg/mL Autoinjectors | 1 |
| | <input type="checkbox"/> Weeks 12+: Inject 80 mg SQ on week 12, & every four weeks after | <input type="checkbox"/> 1x80 mg/mL Autoinjector | |

Injection Training Provided By: Physician's Office Delta Drugs | Dispense As Written

| | |
|--|-------------|
| Physician's Signature: _____ | Date: _____ |
| I AUTHORIZE DELTA DRUGS AND ITS REPRESENTATIVES TO ACT AS AN AGENT TO INITIATE AND EXECUTE THE INSURANCE PRIOR AUTHORIZATION PROCESS. | |